Corresponding Author: Adi Vaknin-Dembinsky, MD, PhD, Neurology Department, Multiple Sclerosis & Immunobiology Research, Hadassah Medical Center, Ein–Kerem, PO Box 12000, Jerusalem 91120, Israel (email@example.com).
Accepted for Publication: August 24, 2021.
Published Online: September 23, 2021. doi:10.1001/jamaneurol.2021.3599
Author Contributions: Drs Vaknin-Dembinsky and Brill had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Brill, Raposo, Vaknin-Dembinsky.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Brill, Haham, Oiknine-Djian, Vaknin-Dembinsky.
Critical revision of the manuscript for important intellectual content: Brill, Rechtman, Zveik, Wolf, Levin, Raposo, Vaknin-Dembinsky.
Statistical analysis: Brill, Rechtman, Zveik.
Administrative, technical, or material support: Brill, Haham, Oiknine-Djian, Raposo, Vaknin-Dembinsky.
Supervision: Wolf, Levin, Vaknin-Dembinsky.
Conflict of Interest Disclosures: Dr Raposo is an employee and shareholder of F. Hoffmann-La Roche Ltd. Dr Vaknin-Dembinsky reported grants from F. Hoffmann-La Roche Ltd during the conduct of the study; personal fees from Roche, Biogen, Genzyme Sanofi, Merck, and Novartis outside the submitted work; and grants from Merck and the Ministry of Health of Israel outside the submitted work. No other disclosures were reported.
Funding/Support: This work was partially supported by F. Hoffmann-La Roche Ltd, which developed and markets ocrelizumab.
Role of the Funder/Sponsor: The funder had a role in the design of the study and review of the manuscript. The funder had no role in the conduct of the study; collection, management, or analysis of the data; preparation or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank all patients who generously donated blood samples and our study nurse Michal Mor, LSN (Hadassah Medical Center). We also thank Sharon Ehrlich, MD (Roche Pharmaceuticals Ltd [Israel]), and Rosetta Pedotti, MD, PhD, Nikki Jessop, MD, and Erwan Muros, MPH (F. Hoffmann-La Roche Ltd), for the scientific discussions and support reviewing the manuscript. No compensation was received.
F , Velay
A , Nazon
et al. Intrafamilial exposure to SARS-CoV-2 associated with cellular immune response without seroconversion, France. Emerg Infect Dis
. 2021;27(1). doi:10.3201/eid2701.203611PubMedGoogle Scholar
AT , Linster
M , Tan
et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep
. 2021;34(6):108728. doi:10.1016/j.celrep.2021.108728PubMedGoogle Scholar
I , Krogsgaard
M , Mulligan
et al. Preliminary results of ongoing, prospective study of antibody and T-cell responses to SARS-CoV-2 in patients with MS on ocrelizumab or other disease-modifying therapies. Neurology
. 2021;96(22):e2783-e2784. doi:10.1212/WNL.0000000000012044Google Scholar
A , Mandel
M , Dreyer-Alster
et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord
. 2021;14:17562864211012835. doi:10.1177/17562864211012835Google Scholar